statement
考慮到領展過往在併購方面的表現參差不齊,投資者或許會質疑此次收購及未來潛在的收購能否真正創造可持續的股東價值。
A statement by 瑞銀. Statements are as reported by the cited publishers — not verified by DecisionGateway.
考慮到領展過往在併購方面的表現參差不齊,投資者或許會質疑:此次收購及未來潛在的收購能否真正創造可持續的股東價值。
Discussion
Related claims
瑞銀表示,考慮到領展過往在併購方面的表現參差不齊,投資者或許會質疑此次收購及未來潛在的收購能否真正創造可持續的股東價值。瑞銀 · statement此次收購可能意味著在即將發布的中期業績中,領展進一步擴大回購規模的空間已收窄。瑞銀 · prediction交易預計於明年首季完成,領展將透過內部資源及債務融資支付收購代價。領展資產管理 · predictionThe investor is concerned about how the company will establish mechanisms to prevent the risk of hostile stake-building by external capital and hostile contest for control after its ownership becomes dispersed.有投資者 · statementAfter the transaction is completed, 領展 will manage three retail assets in Singapore: Eastpoint Mall, Jurong Point and AMK Hub.領展房產基金 · prediction領展宣布從英康保險手中收購新加坡東福坊50.1%的股權,總代價為2.36億新加坡元,這是該基金自2022年以來的首次收購。瑞銀 · statement
More claims by 瑞銀
Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.predictionTigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.statementIf the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.predictionFrontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.statementAfter the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.statement
All claims by 瑞銀